Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can simple reminders keep children safe from malaria after hospital?

NCT ID NCT06601712

Disease control Sponsor: Institut de Recherche Clinique du Benin Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial in Benin tests different ways to help caregivers give children a 3-day course of malaria prevention medicine each month for three months after leaving the hospital. The children, all under 10, were hospitalized with severe malaria or severe anemia. Some families get home visits from community health workers, others get SMS or phone reminders, and some get no extra support. The goal is to see which approach improves adherence to the full 9-dose regimen and reduces hospital readmissions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Post-discharge malaria chemoprevention (PDMC) with adherence support strategies (community health worker home visits or SMS/phone reminders)
What this could lead to
If successful, this could identify the best way to deliver and support malaria prevention after hospital discharge, reducing readmissions and deaths in high-risk children.
What could go wrong
The trial is focused on implementation in one country, and results may not apply elsewhere. Adherence support may not improve outcomes as hoped, and the study is not designed to test the drugs' efficacy directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 648 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Up to 9 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged below 10 years of both sexes * Hospitalised with severe anaemia or severe malaria: Initially hospitalised with haemoglobin below 5.0 g/dl or PCV below 15%, or requirement for blood transfusion for other clinical reasons on or during admission to the hospital, or severe malaria, defined as a requirement for parenteral artesunate in the opinion of the treating clinician and the presence of microscopy or RDT confirmed Plasmodium infection Exclusion Criteria: * Recognised specific other causes of severe anaemia (i.e., trauma, haematological malignancy, known bleeding disorders, such as haemophilia) * Sickle cell anaemia/sickle cell disease * Body weight below 5 kg * HIV infection and cotrimoxazole prophylaxis are not exclusion criteria

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Severe anaemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anemia malaria prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Severe anaemia Severe malaria

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Universitaire de la Mere et de l'Enfant Lagune (CHU-MEL)

    RECRUITING

    Cotonou, Benin

  • Goho Departmental Hospital Centre

    NOT_YET_RECRUITING

    Abomey, Benin

More trials for these conditions

Other studies related to the condition(s) this trial covers.